GlaxoSmithKline Australia
Administration route: 
Intramuscular injection
Vaccine group: 
HPV vaccines

Registered for use in females aged 10 to <46 years.

2vHPV — Recombinant protein particulate (VLP) vaccine containing the major capsid (L1) protein of HPV types 16 and 18

Each 0.5 mL monodose vial or pre-filled syringe contains:

  • 20 µg HPV-16 L1 protein
  • 20 µg HPV-18 L1 protein

These are adjuvanted with AS04. The adjuvant comprises:

  • 0.5 mg aluminium hydroxide
  • 50 µg 3-O-desacyl-4’-monophosphoryl lipid A (MPL)

For detailed advice on vaccine dosage, administration, contraindications and precautions, please visit the relevant disease chapter.

Page history

Last updated: 
4 June 2018
Last reviewed: 
4 June 2018


bivalent HPV vaccine